Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Feb 15, 2022; 14(2): 450-477
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.450
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.450
Figure 4 The effect of frankincense and/or myrrh in the tumor growth of human hepatocellular carcinoma subcutaneously transplanted tumor models.
A: Representative images of tumor size at the end of the experiment; B: Animal weight during the entire oral treatment process; C: Statistical graph of tumor size at the end of the experiment; D: Changes in tumor size during the entire oral treatment process; E: H-E staining of tumors in each group (100×, 400×), scale bars: 100 μm. LF: Low dose of frankincense extract; HF: High dose of frankincense extract; LM: Low dose of myrrh extract; HM: High dose of myrrh extract; LFM: Low dose of frankincense + myrrh extracts; HFM: High dose of frankincense + myrrh extracts. Data represents the mean ± SE. Compared with the model control, aP < 0.05, bP < 0.01, cP < 0.001.
- Citation: Zheng P, Huang Z, Tong DC, Zhou Q, Tian S, Chen BW, Ning DM, Guo YM, Zhu WH, Long Y, Xiao W, Deng Z, Lei YC, Tian XF. Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol 2022; 14(2): 450-477
- URL: https://www.wjgnet.com/1948-5204/full/v14/i2/450.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i2.450